Drug intelligence / Profile preview

BIOK-001

Development stage: Preclinical
Lead developer: BIORCHESTRA
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies

Overview

BIOK-001 is an early-stage genetic therapeutic candidate being developed by BIORCHESTRA for the treatment of neuroinflammatory diseases. While specific molecular targets and the exact nature of the genetic payload remain undisclosed, the program leverages BIORCHESTRA's proprietary Brain Targeting Drug Delivery System (BDDS™). This platform is designed to facilitate the transport of therapeutic oligonucleotides or other genetic materials across the blood-brain barrier (BBB) to reach target cells within the central nervous system. BIOK-001 is currently in the discovery or preclinical stage of development.

Beyond the preview

Go deeper on BIOK-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOK-001.

Explore the full profile